Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a global insulin delivery and diabetes technology company whose news flow centers on product innovation, regulatory milestones, financial performance, and corporate developments. The company manufactures and sells advanced automated insulin delivery systems, including the Tandem Mobi system and the t:slim X2 insulin pump, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology.
News updates for Tandem Diabetes Care often highlight regulatory and product announcements. Recent examples include FDA 510(k) clearance for the SteadiSet infusion set for up to seven days of use, FDA clearance for the Android version of the Tandem Mobi mobile app, and integration of the t:slim X2 pump with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor in the United States. The company also issues press releases on software and mobile app availability, such as the Tandem t:slim mobile app launch for Android and iOS users in Canada.
Investors and observers can also expect regular earnings and guidance updates. Tandem Diabetes Care reports quarterly financial results and provides full-year guidance, with related press releases and conference call details disclosed publicly. Additional news items cover corporate governance, such as the appointment of new board members and committee assignments, as well as certifications like ISO/IEC 27001:2022 for information security.
This news page for TNDM aggregates these types of announcements, including earnings releases, regulatory clearances, product compatibility updates, conference presentations, and technology rollouts. It provides a single location to follow how Tandem Diabetes Care’s insulin delivery systems, digital platforms, and global initiatives are evolving over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Tandem Diabetes Care (NASDAQ: TNDM) announced a company update presentation scheduled for May 10, 2023, at 4:40 PM Eastern Time during the BofA Securities 2023 Health Care Conference. The live event will be accessible via webcast, with an archive available for 30 days afterward.
The presentation will highlight Tandem's commitment to innovation in insulin delivery and diabetes technology, emphasizing their human-centered design approach. The company manufactures the t:slim X2 insulin pump featuring Control-IQ technology, aimed at enhancing the management of diabetes for users and healthcare providers.
For more details, the webcast link can be found on Tandem’s Investor Center website under the “Events & Presentations” section.
Tandem Diabetes Care (NASDAQ: TNDM) announced a publication in Diabetes Technology & Therapeutics of a meta-analysis from three randomized controlled trials showcasing its Control-IQ advanced hybrid closed-loop technology. The study highlights significant improvements in glucose control, with an average increase in time in range of 2.8 hours and a reduction in hemoglobin A1c levels across diverse demographics, including ages 2 to 72. Those with the highest baseline blood sugar benefited most from the automatic correction bolusing feature. The results indicate broad applicability of Control-IQ technology, enhancing diabetes management effectiveness. Notably, the technology's comprehensive data set supports its advantages over competing automated insulin delivery systems.
Tandem Diabetes Care plans to release its first quarter 2023 results on May 3, 2023, after market close. A conference call will take place at 4:30 PM ET to discuss financial and operating results. Investors can access the live webcast on the company's Investor Center website. The event will provide insights into the company's performance, focusing on innovative diabetes technology products such as the t:slim X2 insulin pump with Control-IQ technology. Tandem Diabetes Care aims to enhance the experience for individuals managing diabetes through its human-centered approach.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced favorable results from the Pediatric Artificial Pancreas (PEDAP) Clinical Trial, published in the New England Journal of Medicine. Children aged 2-5 using the t:slim X2 insulin pump with Control-IQ technology experienced an approximate 3-hour daily increase in time in range compared to standard insulin treatments. Key findings showed a 12.4% adjusted mean difference in time in range and a 0.5% decrease in Hemoglobin A1c levels. The trial included 101 participants, with 94% system usability, indicating significant improvements in glucose control.